Middleton & Co. Inc. MA Cuts Stock Holdings in AbbVie Inc. $ABBV

Middleton & Co. Inc. MA decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 4.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 82,904 shares of the company’s stock after selling 3,666 shares during the period. AbbVie comprises about 1.7% of Middleton & Co. Inc. MA’s holdings, making the stock its 15th largest position. Middleton & Co. Inc. MA’s holdings in AbbVie were worth $15,389,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of the stock. Nuveen LLC purchased a new stake in shares of AbbVie during the first quarter valued at approximately $1,819,154,000. Assenagon Asset Management S.A. increased its position in shares of AbbVie by 550.9% during the second quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock valued at $804,116,000 after acquiring an additional 3,666,521 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of AbbVie by 31.6% during the first quarter. Goldman Sachs Group Inc. now owns 14,646,908 shares of the company’s stock valued at $3,068,820,000 after acquiring an additional 3,519,187 shares during the last quarter. Kingstone Capital Partners Texas LLC purchased a new stake in shares of AbbVie during the second quarter valued at approximately $581,817,000. Finally, Invesco Ltd. increased its position in shares of AbbVie by 17.5% during the first quarter. Invesco Ltd. now owns 8,367,049 shares of the company’s stock valued at $1,753,064,000 after acquiring an additional 1,246,863 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on ABBV shares. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. HSBC set a $225.00 price target on AbbVie in a research report on Thursday, October 2nd. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Erste Group Bank downgraded AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Finally, Daiwa America raised AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $238.05.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $198.42, for a total value of $8,407,055.40. Following the sale, the executive vice president owned 177,292 shares of the company’s stock, valued at $35,178,278.64. This trade represents a 19.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.25% of the stock is currently owned by insiders.

AbbVie Stock Performance

NYSE:ABBV opened at $216.96 on Thursday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.61 and a current ratio of 0.74. AbbVie Inc. has a 52-week low of $163.81 and a 52-week high of $244.81. The firm has a market cap of $383.27 billion, a price-to-earnings ratio of 103.31, a PEG ratio of 1.42 and a beta of 0.50. The business’s fifty day moving average is $222.84 and its 200 day moving average is $201.84.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the company posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.